Predicting potential epitopes of structural proteins for Alpha, Delta, and Omicron variants of SARS-CoV-2
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background Due to the emergence of highly transmissible variants, such as the recombinant subvariant XEC, SARS-CoV-2 continues to spread worldwide. Epitope-based vaccines have been developed since conventional antigen-based vaccines may not provide protection against all SARS-CoV-2 variants. These vaccines target multiple epitopes that interact with antibodies or T-cell receptors and are being investigated to enhance immune responses. Objective This study investigates the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins of SARS-CoV-2 across different variants, including Alpha, Delta, and Omicron, to identify potential epitopes that could contribute to the development of next-generation vaccines. Methods This study used several freely accessible web-based tools and open source to identify the potential epitopes. Antigenicity, allergenicity, and toxicity prediction were evaluated using VaxiJen v2.0, AntigenPro, AllerTop v2.0, and ToxinPred. Cytotoxic T lymphocyte (CTL), helper T lymphocyte (HTL), and linear B lymphocyte (LBL) epitopes were predicted using the Immune Epitope Database (IEDB) server. Results VaxiJen v2.0 indicated that the E protein demonstrates lower antigenicity than the S, M, and N proteins among the selected variants. AntigenPro analysis revealed that in the Alpha (B.1), Delta (AY.23), and Omicron (BQ.1.23) variants, only the S and N proteins surpassed the antigenicity threshold. However, in the Omicron BA.5.2 and BA.1.1 variants, only the E protein was found to be below the threshold. Further analysis showed that only the S (17 CTL, 6 HTL, and 13 LBL) and N (7 CTL, 6 HTL, and 1 LBL) proteins contain potential T-and B-cell epitopes. Conclusions This study provides valuable insights into potential epitopes derived from various SARS-CoV-2 variants, which may be utilized for the development of epitope-based vaccines.
Fields of Study & Subjects
vaccines and immunoinformatics approaches
SARS-CoV-2 and COVID-19 Research
Immunotherapy and Immune Responses
Publication details
- Journal / source
- Heliyon
- Volume
- 12
- Issue
- 6
- Pages
- e44788–e44788
- Publication date
- 31 March 2026
- Language
- EN